These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 9649677)

  • 1. Coagulation factor XIII in scleroderma.
    Jullien D; Souillet AL; Faure M; Claudy A
    Eur J Dermatol; 1998 Jun; 8(4):231-4. PubMed ID: 9649677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapeutic action of coagulation factor XIII in scleroderma. 20 cases].
    Thivolet J; Perrot H; Meunier F; Bouchet B
    Nouv Presse Med; 1975 Nov; 4(39):2779-82. PubMed ID: 1105424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coagulation factor XIII, endothelial damage and systemic sclerosis.
    Marzano AV; Federici AB; Gasparini G; Mannucci PM; Caputo R; Berti E
    Eur J Dermatol; 2000; 10(1):14-7. PubMed ID: 10694291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of progressive systemic sclerosis using factor XIII.
    Guillevin L; Chouvet B; Mery C; De Gery A; Thivolet J; Godeau P; Delbarre F
    Pharmatherapeutica; 1985; 4(2):76-80. PubMed ID: 3903781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coagulation factor XIII: a multifunctional transglutaminase with clinical potential in a range of conditions.
    Dickneite G; Herwald H; Korte W; Allanore Y; Denton CP; Matucci Cerinic M
    Thromb Haemost; 2015 Apr; 113(4):686-97. PubMed ID: 25652913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Bronchiolo-alveolar carcinoma complicating systemic scleroderma under long-term treatment with factor XIII].
    Grivaux M; Pieron R
    Rev Pneumol Clin; 1987; 43(2):102-3. PubMed ID: 3039643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of systemic scleroderma].
    Priollet P; Baudot N; Fiessinger JN; Vayssairat M; Housset E
    Ann Dermatol Venereol; 1984; 111(6-7):595-607. PubMed ID: 6388467
    [No Abstract]   [Full Text] [Related]  

  • 8. Double filtration plasmapheresis can decrease factor XIII Activity.
    Hanafusa N; Kondo Y; Suzuki M; Nakao A; Noiri E; Fujita T
    Ther Apher Dial; 2007 Jun; 11(3):165-70. PubMed ID: 17497996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Long-term treatment of systemic scleroderma with coagulation factor XIII. Developmental monitoring, especially of respiratory function].
    Euller-Ziegler L; Corolleur YR; Marcou J; Commandre F; Grisot C; Ziegler G
    Rev Rhum Mal Osteoartic; 1984 Oct; 51(9):503-5. PubMed ID: 6505601
    [No Abstract]   [Full Text] [Related]  

  • 10. Factor XIII deficiency.
    Hsieh L; Nugent D
    Haemophilia; 2008 Nov; 14(6):1190-200. PubMed ID: 19141159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of generalized scleroderma with factor XIII. Study of 25 cases].
    Guillevin L; Chouvet B; Mery C; Thivolet J; Godeau P; Delbarre F
    Rev Med Interne; 1982; 3(3):273-7. PubMed ID: 6758093
    [No Abstract]   [Full Text] [Related]  

  • 12. Prophylaxis in rare coagulation disorders -- factor XIII deficiency.
    Nugent DJ
    Thromb Res; 2006; 118 Suppl 1():S23-8. PubMed ID: 16616323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Global improvement of systemic scleroderma under long-term administration of octreotide.
    Descamps V; Duval X; Crickx B; Bouscarat F; Coffin B; Belaich S
    Eur J Dermatol; 1999 Sep; 9(6):446-8. PubMed ID: 10491499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced levels of coagulation factor XIII in patients with advanced tumor disease.
    Born P; Lippl F; Ulm K; Gerein P; Lersch C; Eckel F; Fischer G; Sandschin W; Dlaska U; Classen M
    Hepatogastroenterology; 2000; 47(31):194-8. PubMed ID: 10690608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Favorable effects of plasma factor XIII on lower esophageal sphincter pressure of progressive systemic sclerosis.
    Maekawa Y; Nogita T; Yamada M
    Arch Dermatol; 1987 Nov; 123(11):1440-1. PubMed ID: 3674907
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety of recombinant human factor XIII in a cynomolgus monkey model of extracorporeal blood circulation.
    Ponce R; Armstrong K; Andrews K; Hensler J; Waggie K; Heffernan J; Reynolds T; Rogge M
    Toxicol Pathol; 2005; 33(6):702-10. PubMed ID: 16243775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of systemic scleroderma with factor XIII in 86 patients, with long-term follow-up].
    Guillevin L; Euller-Ziegler L; Chouvet B; De Gery A; Chassoux G; Lafay P; Ziegler G; Godeau P; Amor B; Thivolet J
    Presse Med; 1985 Dec; 14(46):2327-9. PubMed ID: 2935830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of clinical efficacy of additional factor XIII treatment in patients with steroid refractory colitis. The Factor XIII Study Group.
    Bregenzer N; Caesar I; Andus T; Hämling J; Malchow H; Schreiber S; Schölmerich J
    Z Gastroenterol; 1999 Oct; 37(10):999-1004. PubMed ID: 10549094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial.
    Clements PJ; Hurwitz EL; Wong WK; Seibold JR; Mayes M; White B; Wigley F; Weisman M; Barr W; Moreland L; Medsger TA; Steen VD; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner SR; Andrews B; Abeles M; Furst DE
    Arthritis Rheum; 2000 Nov; 43(11):2445-54. PubMed ID: 11083267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Substitution with blood coagulation factor XIII concentrates in patients with acute leukemia].
    Rasche H
    Beitr Infusionther Klin Ernahr; 1986; 15():179-86. PubMed ID: 3530242
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.